Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Ocular Therapeutix Inc

OCUL ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Mid Cap Analyst: BUY

Last Close

$10.04

▼ -0.59%

Market Cap $2.20B · Vol 556.38K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$2.20B

Mid Cap

Div Yield

N/A

EPS Growth

-8.53%

YoY

RSI (14)

72.44

Momentum

Beta

0.98

vs Market

52W High

$16.42

38.84% below

52W Low

$6.24

60.90% above

Volume

556.38K

Avg 680.86K

P/B

4.01

Price-to-book

ROE

-54.85%

Return on equity

Free Float

97.88%

Public shares

Shariah Compliance8 STANDARDS

✗ Ocular Therapeutix Inc (OCUL) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does OCUL pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+9.25%

+3.51%

+5.68%

+13.06%

YTD

-17.30%

-20.63%

+122.62%

-6.69%

Financials & Valuation

TTM · Annual

Total Revenue	$51.95M
Net Income	$-265,939,000.00
Revenue Growth (YoY)	+0.12%
Gross Margin	87.35%
Operating Margin	-519.75%
Net Profit Margin	-511.90%
ROE	-54.85%
ROA · ROIC	-42.01% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	43.75
P/B	4.01
P/FCF	N/A
EPS Growth	-8.53%
Outstanding Shares	219.62M

Technical Indicators

50-Day SMA	$9.25
200-Day SMA	$9.98
RSI (14)	72.44
Beta	0.98
52-Week High	$16.42
52-Week Low	$6.24

Volume Today	556.38K
Avg Daily Volume (30D)	680.86K
Relative Volume	0.82x
Volatility (10D)	38.30
Volatility (30D)	51.11
Free Float	97.88%

Analyst Consensus

BUY

Current Price $10.04

Mean Target $26.73

52W Low$6.24 52W High$16.42

Current

Target

$6.24 $16.42

Current Analyst target

+166.21% upside potential · 12 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001V0FT93

ISINUS67576A1007

CountryUnited States of America

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Ocular Therapeutix, Inc. is an integrated biopharmaceutical company. AXPAXLI, also known as OTX-TKI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases.